• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
JNJ-26854165

JNJ-26854165

Product ID J5237
Cas No. 881202-45-5
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $117.20 In stock
5 mg $211.10 In stock
25 mg $633.00 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

JNJ-26854165 is an inhibitor of E3 ligase MDM2 that also indirectly activates p53. This compound exhibits anticancer chemotherapeutic activity, decreasing survival of various cancer cell lines and delaying tumor growth in animal models. JNJ-26854165 also induces S-phase cell cycle arrest and decreases cholesterol efflux and transport in mantle cell lymphoma and multiple myeloma cells.

Product Info

Cas No.

881202-45-5

Purity

≥98%

Formula

C21H20N4

Formula Wt.

328.42

IUPAC Name

N-[2-(1H-Indol-3-yl)ethyl]-N'-(4-pyridinyl)-1,4-benzenediamine

Synonym

Serdemetan, JNJ26854165, JNJ 26854165

Solubility

DMSO Solubility: 66 mg/mL (200.96 mM)

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

J5237 MSDS PDF

Info Sheet

J5237 Info Sheet PDF

References

Jones RJ, Gu D, Bjorklund CC, et al. The novel anticancer agent JNJ-26854165 induces cell death through inhibition of cholesterol transport and degradation of ABCA1. J Pharmacol Exp Ther. 2013 Sep;346(3):381-92. Erratum in: J Pharmacol Exp Ther. 2013 Nov;347(2):540. PMID: 23820125.

Chargari C, Leteur C, Angevin E, et al. Preclinical assessment of JNJ-26854165 (Serdemetan), a novel tryptamine compound with radiosensitizing activity in vitro and in tumor xenografts. Cancer Lett. 2011 Dec 22;312(2):209-18. PMID: 21937165.

Kojima K, Burks JK, Arts J, et al. The novel tryptamine derivative JNJ-26854165 induces wild-type p53- and E2F1-mediated apoptosis in acute myeloid and lymphoid leukemias. Mol Cancer Ther. 2010 Sep;9(9):2545-57. PMID: 20736344.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • L1782

    Levodopa

    Endogenous catecholamine precursor, also found ...

    ≥98%
  • T1012

    13-TES-Baccatin III

    Synthesis impurity

    ≥98%
  • G0000

    G250.A2 Peptide

    Peptide, carbonic anhydrase G250 epitope.

    ≥95%
  • D0033

    Daidzin

    Isoflavone, phytoestrogen, found in soy.

    ≥98%
  • N1978

    Neurokinin B

    Neuromodulator, biomarker

    ≥95%
  • C0243

    Calcitonin Gene Related Peptide (8-37), human

    Calcitonin-family peptide frgament, involved in...

    ≥95%
  • T8004

    Tubeimoside I

    Triterpene saponin originally found in Bolboste...

    ≥96%
  • B6957

    Bromhexine Hydrochloride

    Synthetic derivative of vasicine, mucolytic.

    ≥98%
  • O9458

    Oxolinic Acid

    Fluoroquinolone; bacterial DNA gyrase inhibitor...

    ≥98%
  • Y0002

    Y-320

    Phenylpyrazoleanilide; IL-17 production inhibit...

    ≥98%
  • A0778

    ABT-737

    BH3 mimetic; Bcl-2, Bxl-xl, Bcl-w inhibitor.

    ≥98%
  • A081014

    Acalabrutinib

    Inhibitor of Bruton’s tyrosine kinase (BTK).<...

    ≥99%
  • L0360

    Lapatinib Ditosylate Monohydrate

    EGFR inhibitor.

    ≥99%
  • C9611

    Cyclosporin A

    Cyclic peptide; calcineurin inhibitor.

    ≥98%
  • R0247

    Raltegravir

    HIV integrase inhibitor.

    ≥99%
  • A6818

    Arenobufagin

    Bufanolide steroid found in Bufo arenarum;VEGFR...

    ≥98%
  • A5219

    Anethole Trithione

    Oltipraz analog, salivary gland secretion enhan...

    ≥98%
  • R5661

    Ropinirole Hydrochloride

    Indoline; D2/3 agonist.

    ≥99%
  • A0816

    Acemetacin

    Glycolic acid ester prodrug of indomethacin, NS...

    ≥98%
  • G8850

    GW-5074

    c-Raf inhibitor.

    ≥98%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only